Drug intelligence / Profile preview

PVT-1

Development stage: Unknown
Lead developer: PlusVitech
Modality: Small Molecules
Administration: Oral

Overview

PVT-1 is an orally administrable, investigational drug being studied for the treatment of advanced non-small cell lung cancer (NSCLC). It is designed to target a specific therapeutic pathway in cancer cells and has demonstrated efficacy in preclinical models. The drug is currently being evaluated in clinical trials for patients with advanced NSCLC who lack EGFR, ALK, or ROS1 mutations and have not responded to other treatments. PVT-1 aims to provide a new therapeutic option for patients with limited alternatives. The precise molecular mechanism of action has not been publicly disclosed as of June 2025[7][8].

Beyond the preview

Go deeper on PVT-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVT-1.

Explore the full profile